Continuous venovenous hemofiltration with citrate-based replacement fluid: Efficacy, safety, and impact on nutrition

被引:29
作者
Bihorac, A [1 ]
Ross, EA [1 ]
机构
[1] Univ Florida, Div Nephrol Hypertens & Transplantat, Gainesville, FL 32610 USA
关键词
continuous venovenous hernofiltration (CVVH); anticoagulation; citrate; continuous renal replacement therapy; nutrition; ultrafiltration; ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; CARDIAC-SURGERY; HIGH-RISK; ANTICOAGULATION; THERAPY; HEMODIAFILTRATION; PROTEIN; SCORE;
D O I
10.1053/j.ajkd.2005.08.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Citrate-based continuous venovenous hemofiltration (CVVH) replacement fluids provide effective and simple regional anticoagulation. However, concern over toxicity has limited citrate use, especially at the high filtration rates advocated for better outcomes. We used volumes of 72 L/d in patients at high risk for bleeding and investigated the treatment's efficacy, safety, and clinical results, especially with regard to nutrition supplementation. Methods: A standard replacement solution (trisodium citrate, 13.3 mmol/L) was infused at up to 3 L/h in predilution CVVH, and ultrafiltration was increased further for net fluid removal. Calcium was repleted centrally. We retrospectively evaluated metabolic control, citrate toxicity, circuit patency, hemorrhagic complications, hemodynamics, vasopressor use, nutrition, renal recovery, and mortality. Results Seventy-six patients with 766 CVVH patient-days were analyzed. Mean replacement fluid rate was 31 mL/kg/h (35 mmol/h of citrate), with hemofiltration of 35 mL/kg/h (67 +/- 11 L/d). No significant bleeding, citrate toxicity, or hypocalcemia was observed, and 74% required additional alkali therapy. Dialyzer patency was 58% at 48 hours. Control of fluid, electrolytes, and azotemia was excellent (serum creatinine level, 1.7 mg/dL [150 mu mol/L]; blood urea nitrogen, 42 mg/dL [15 mmol/L]). Fluid removal permitted protein (1.7 g/kg/d) and calorie (30 kcal/kg/d) nutrition in high fluid volumes. Vasopressor use and central pressures decreased significantly. Cumulative 28-day intensive care unit survival was 58%, and 41% of these patients had renal recovery in the intensive care unit. Thirty percent of the entire cohort survived the hospitalization, and 53% of these patients recovered renal function. Conclusion: CVVH with 3 L/h of citrate-based replacement fluid is a safe, efficient, and simple technique in patients at high risk for bleeding. It allows superb control of uremia and fluid balance and thereby permits aggressive nutritional support. Am J Kidney Dis 46:908-918. (c) 2005 by the National Kidney Foundation, Inc.
引用
收藏
页码:908 / 918
页数:11
相关论文
共 31 条
  • [1] Anticoagulation in continuous renal replacement therapy
    Abramson, S
    Niles, JL
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1999, 8 (06) : 701 - 707
  • [2] CITRATE ANTICOAGULATION DURING INVIVO SIMULATION OF SLOW HEMOFILTRATION
    AHMAD, S
    YEO, KT
    JENSEN, WM
    DELLANDICHO
    GREGORY, B
    MORITZ, JL
    KENNY, M
    [J]. BLOOD PURIFICATION, 1990, 8 (04) : 177 - 182
  • [4] A prospective comparative study of moderate versus high protein intake for critically ill patients with acute renal failure
    Bellomo, R
    Seacombe, J
    Daskalakis, M
    Farmer, M
    Wright, C
    Parkin, G
    Boyce, N
    [J]. RENAL FAILURE, 1997, 19 (01) : 111 - 120
  • [5] Bellomo R, 1998, KIDNEY INT, V53, pS125
  • [6] Elimination of proinflammatory cytokines in pediatric cardiac surgery: Analysis of ultrafiltration method and filter type
    Berdat, PA
    Eichenberger, E
    Ebell, J
    Pfammatter, JP
    Pavlovic, M
    Zobrist, C
    Gygax, E
    Nydegger, U
    Carrel, T
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (06) : 1688 - 1696
  • [7] Outcome and predictive factors of acute renal failure in the intensive care unit
    Bernieh, B
    Al Hakim, M
    Boobes, Y
    Siemkovics, E
    El Jack, H
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (06) : 1784 - 1787
  • [8] BIHORAC A, 2004, J AM SOC NEPHROL, V15, pA582
  • [9] CHIMA CS, 1993, J AM SOC NEPHROL, V3, P1516
  • [10] Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions
    Cointault, O
    Kamar, N
    Bories, P
    Lavayssiere, L
    Angles, O
    Rostaing, L
    Genestal, M
    Durand, D
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (01) : 171 - 178